Fulgent Genetics Inc
NASDAQ:FLGT

Watchlist Manager
Fulgent Genetics Inc Logo
Fulgent Genetics Inc
NASDAQ:FLGT
Watchlist
Price: 18.68 USD 0.92% Market Closed
Market Cap: 571.4m USD
Have any thoughts about
Fulgent Genetics Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one FLGT stock under the Base Case scenario is 18.96 USD. Compared to the current market price of 18.68 USD, Fulgent Genetics Inc is Undervalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FLGT Relative Value
Base Case
18.96 USD
Undervaluation 1%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
79
vs Industry
47
Median 3Y
2.3
Median 5Y
2.6
Industry
2.3
Forward
2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
3.5
Industry
23.1
Forward
56
More Details
52.1
P/OCF
P/OCF
Price to OCF
52.1
vs History
20
vs Industry
25
Median 3Y
15.5
Median 5Y
16.5
Industry
14.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
2
Median 3Y
3.9
Median 5Y
4.4
Industry
20.1
More Details
0.5
P/B
P/B
Price to Book Value
0.5
vs History
98
vs Industry
74
Median 3Y
0.8
Median 5Y
1.3
Industry
2.2
More Details
1.3
EV/S
EV/S
Enterprise Value to Sales
1.3
vs History
71
vs Industry
63
Median 3Y
1.3
Median 5Y
1.6
Industry
2.4
Forward
1.2
More Details
3.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.6
vs History
47
vs Industry
57
Median 3Y
2.8
Median 5Y
3.3
Industry
5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
2.1
Industry
12.7
Forward
-37
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
1.5
Industry
17.1
Forward
-7.6
More Details
32.7
EV/OCF
EV/OCF
Enterprise Value to OCF
32.7
vs History
22
vs Industry
40
Median 3Y
7.4
Median 5Y
8
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
23
Median 3Y
3.9
Median 5Y
5.8
Industry
18
More Details
0.4
EV/IC
EV/IC
Enterprise Value to IC
0.4
vs History
95
vs Industry
80
Median 3Y
0.6
Median 5Y
1.3
Industry
1.9
More Details

Multiples Across Competitors

FLGT Competitors Multiples
Fulgent Genetics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Fulgent Genetics Inc
NASDAQ:FLGT
570.4m USD 2.1 -3.5 -5.6 -4
US
Cigna Corp
NYSE:CI
78.7B USD 0.3 25.9 8.1 10.4
US
Cigna Group
XMUN:CGN
75.6B EUR 0.3 25.8 8 10.4
US
CVS Health Corp
NYSE:CVS
56.5B USD 0.2 11.3 9.6 9.6
DE
Fresenius Medical Care AG
XMUN:FME
25.8B EUR 1.3 48.6 11.2 25.8
DE
Fresenius SE & Co KGaA
XETRA:FRE
18.8B EUR 0.9 -49.1 9.3 19
US
Laboratory Corporation of America Holdings
NYSE:LH
19.3B USD 1.5 44.4 13.2 20.5
US
Quest Diagnostics Inc
NYSE:DGX
17.1B USD 1.8 20.5 12.3 16.7
US
R1 RCM Inc
NASDAQ:RCM
16.9B USD 6.9 -275.9 36.7 94.9
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
12.8B EUR 0.7 24.3 7 16.3
US
DaVita Inc
NYSE:DVA
12.9B USD 1 15.5 8 11.2
P/E Multiple
Earnings Growth P/E to Growth
US
Fulgent Genetics Inc
NASDAQ:FLGT
Average P/E: 27
Negative Multiple: -3.5 		N/A N/A
US
Cigna Corp
NYSE:CI
25.9
96%
0.3
US
C
Cigna Group
XMUN:CGN
25.8
96%
0.3
US
CVS Health Corp
NYSE:CVS
11.3
8%
1.4
DE
Fresenius Medical Care AG
XMUN:FME
48.6
127%
0.4
DE
Fresenius SE & Co KGaA
XETRA:FRE
Negative Multiple: -49.1 N/A N/A
US
Laboratory Corporation of America Holdings
NYSE:LH
44.4
263%
0.2
US
Quest Diagnostics Inc
NYSE:DGX
20.5
41%
0.5
US
R1 RCM Inc
NASDAQ:RCM
Negative Multiple: -275.9
4 308%
N/A
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
24.3
127%
0.2
US
DaVita Inc
NYSE:DVA
15.5
61%
0.3

See Also

Summary
FLGT intrinsic value, competitors valuation, and company profile.
DCF Valuation
FLGT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FLGT stock valuation using valuation multiples.
Wall Street Estimates
FLGT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FLGT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 211,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.